Tris Pharma has enhanced its supply chain, increased manufacturing capacity, and added to its management team. Tris has received five new ANDA approvals from the FDA, and has several ANDAs and two NDAs pending approval. To accommodate these projects, Tris initiated the expansion of its manufacturing capacity earlier this year and is midway through the 15-month project that will expand the facility from 90,000 sq. ft. to approximately 200,000 sq. ft. The first phase doubles the company’s cGMP capacity.
 
Ketan Mehta, Tris’ president and chief executive officer, said, “Expanding manufacturing capacity is a critical part of the growth equation but equally important is having the right team to manage our dynamic and complex supply chain. To that end, we have added several new managerial positions and were very fortunate to have recruited David Palew, a seasoned supply chain executive, for the newly created position of senior director of Supply Chain.”
 
Mr. Palew has more than 15 years of supply chain experience at large pharmaceutical companies such as Block Drug, Alpharma, Barr/Teva and G&W Laboratories. He will lead the company’s supply chain team, co-lead the ERP implementation team, and will work closely with suppliers and external marketing partners.